Two Sigma Securities LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 740.7% during the first quarter, Holdings Channel reports. The institutional investor owned 47,231 shares of the company’s stock after buying an additional 41,613 shares during the period. Johnson & Johnson makes up 1.2% of Two Sigma Securities LLC’s portfolio, making the stock its 9th largest position. Two Sigma Securities LLC’s holdings in Johnson & Johnson were worth $5,883,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in JNJ. Norges Bank purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $3,220,322,000. Schwab Charles Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 1.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock worth $1,388,775,000 after buying an additional 201,703 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Johnson & Johnson by 1.2% in the first quarter. Fisher Asset Management LLC now owns 11,093,898 shares of the company’s stock worth $1,381,745,000 after buying an additional 136,764 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Johnson & Johnson by 0.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock worth $990,041,000 after buying an additional 42,144 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Johnson & Johnson by 5.6% in the fourth quarter. Macquarie Group Ltd. now owns 6,851,198 shares of the company’s stock worth $789,328,000 after buying an additional 362,616 shares in the last quarter. Hedge funds and other institutional investors own 66.06% of the company’s stock.

Johnson & Johnson (NYSE JNJ) traded up 0.01% during trading on Friday, reaching $133.10. 4,270,571 shares of the company were exchanged. The firm’s 50 day moving average price is $133.09 and its 200-day moving average price is $126.30. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The stock has a market capitalization of $357.24 billion, a price-to-earnings ratio of 22.52 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.74 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

WARNING: “Johnson & Johnson (NYSE:JNJ) is Two Sigma Securities LLC’s 9th Largest Position” was originally published by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/12/johnson-johnson-nysejnj-is-two-sigma-securities-llcs-9th-largest-position.html.

A number of analysts have commented on JNJ shares. BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Jefferies Group LLC reissued a “hold” rating and issued a $135.00 price objective (down from $140.00) on shares of Johnson & Johnson in a research report on Sunday, May 14th. Royal Bank Of Canada reissued a “buy” rating and issued a $128.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 15th. Atlantic Securities lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective on the stock. in a research report on Friday, July 21st. Finally, Barclays PLC reissued an “equal weight” rating and issued a $130.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research report on Monday, April 17th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $133.72.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.